stockportfolio.pro
Qiagen N.V. (QGEN)
Healthcare · Diagnostics & Research · NYSE
Qiagen N.V. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.14B | $1.97B | $1.98B | $2.09B |
| Gross profit | $1.38B | $1.23B | $967.35M | $1.30B |
| Net income | $423.21M | $341.30M | $83.59M | $424.88M |
| Net margin | 19.8% | 17.4% | 4.2% | 20.3% |
Source: Qiagen N.V. SEC filings (10-K).
What growth is priced into QGEN stock?
At today's market cap of $7.60B, Qiagen N.V. is priced for free-cash-flow growth of about 5.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $447.20M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Qiagen N.V. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track QGEN in your portfolio →
Qiagen N.V. financial history by metric
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Qiagen N.V. — frequently asked questions
What is Qiagen N.V.'s revenue?
Qiagen N.V. (QGEN) reported revenue of $2.09B for fiscal year 2025, up 5.7% from the prior year, according to its SEC filings.
Is Qiagen N.V. profitable?
Yes. QGEN earned net income of $424.88M in fiscal 2025, a net margin of 20.3%.
What is QGEN's P/E ratio?
Qiagen N.V. trades at a price-to-earnings ratio of about 18.8 based on the latest data in our nightly-refreshed cache.
How fast is Qiagen N.V. growing?
QGEN's revenue grew at roughly -0.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Qiagen N.V. have?
As of fiscal year 2025, QGEN carried roughly $1.65B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Qiagen N.V.'s gross margin?
QGEN's gross margin was 62.2% in fiscal 2025 — gross profit of $1.30B on revenue of $2.09B.
What is Qiagen N.V.'s market cap?
Qiagen N.V. (QGEN) has a market capitalization of about $7.60B, based on the latest data in our nightly-refreshed cache.
When does Qiagen N.V.'s fiscal year end?
QGEN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into QGEN stock?
At today's market cap of $7.60B, Qiagen N.V. is priced for free-cash-flow growth of about 5.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $447.20M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Qiagen N.V.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.